1083326-75-3 Usage
Description
N-[2-Methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-pyridinyl]-methanesulfonamide, also known as MLN2480, is a potent and selective inhibitor of the protein deacetylase enzyme. It is a chemical compound belonging to the class of methanesulfonamides and has shown promising therapeutic potential in the treatment of cancer. MLN2480 works by targeting the activity of the protein deacetylase enzyme, which plays a crucial role in the regulation of gene expression and cellular processes. Its unique chemical structure and mechanism of action make it a valuable tool for further research in the field of epigenetics and cancer biology.
Uses
Used in Cancer Therapy:
N-[2-METHOXY-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-PYRIDINYL]-METHANESULFONAMIDE is used as a therapeutic agent for the treatment of cancer. It exhibits antitumor activity in various cancer types by inhibiting the protein deacetylase enzyme, which is involved in the regulation of gene expression and cellular processes. This inhibition can lead to the suppression of tumor growth and progression.
Used in Epigenetics Research:
N-[2-METHOXY-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-PYRIDINYL]-METHANESULFONAMIDE is used as a research tool in the field of epigenetics. Its unique chemical structure and mechanism of action allow scientists to study the role of protein deacetylase enzymes in gene regulation and their potential as therapeutic targets for various diseases, including cancer.
Used in Cancer Biology Research:
N-[2-METHOXY-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-PYRIDINYL]-METHANESULFONAMIDE is used as a research compound in cancer biology. It helps researchers understand the molecular mechanisms underlying cancer development and progression, as well as identify potential therapeutic targets for the development of novel cancer therapies.
Used in Drug Development:
N-[2-METHOXY-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-PYRIDINYL]-METHANESULFONAMIDE is used as a potential candidate for the development of novel cancer therapies. Its potent and selective inhibition of the protein deacetylase enzyme, along with its demonstrated antitumor activity in various cancer types, makes it a promising candidate for further research and development in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 1083326-75-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,8,3,3,2 and 6 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1083326-75:
(9*1)+(8*0)+(7*8)+(6*3)+(5*3)+(4*2)+(3*6)+(2*7)+(1*5)=143
143 % 10 = 3
So 1083326-75-3 is a valid CAS Registry Number.
1083326-75-3Relevant articles and documents
Cnoline compound PI3K kinase inhibitor as well as preparation method and application thereof in pharmacy
-
Paragraph 0149-0150; 0152, (2021/06/02)
The invention provides a cinnoline compound PI3K kinase inhibitor as shown in a formula I. In the cinnoline compound PI3K kinase inhibitor, and R1, R2 and R3 are defined in the specification. The invention also provides a pharmaceutical composition of the
Design, synthesis, and biological evaluation of some novel 4-aminoquinazolines as Pan-PI3K inhibitors
Ding, Huai-Wei,Wang, Shu,Qin, Xiao-Chun,Wang, Jian,Song, Hong-Rui,Zhao, Qing-Chun,Song, Shao-Jiang
, p. 2729 - 2740 (2019/05/17)
A series of 4-aminoquinazolines derivatives containing hydrophilic group were designed and identified as potent Pan-PI3K inhibitors in this study. The results of antiproliferative assays in vitro showed that this series of compounds had strong inhibition of tumor growth, especially compound 7b for MCF-7 cells but weak inhibition to normal cells. PI3K kinase assay showed that 7b had high activity for three PI3K isoforms with the IC50 values of picomole. The western blot assay indicated that 7b could decrease the phospho-Akt (S473) in a dose-dependent manner. Further experiments showed that 7b could induce apoptosis in MCF-7 cells. Four key hydrogen bonding interactions were found in the docking of 7b with PI3K kinase. All these results suggested that 7b is a potent PI3K inhibitor and could be considered as a potential candidate for the development of anticancer agents.
Development of Flexible and Scalable Routes to Two Phosphatidinylinositol-3-kinase Delta Inhibitors via a Common Intermediate Approach
Edney, Dean,Hulcoop, David G.,Leahy, John H.,Vernon, Lois E.,Wipperman, Mark D.,Bream, Robert N.,Webb, Michael R.
, p. 368 - 376 (2018/03/22)
This paper describes the discovery and development of a flexible route to two candidate drug molecules by a common intermediate approach. Key reactions include Negishi and Suzuki couplings to form biaryl bonds. Conditions for a Miyaura borylation of heteroaryl bromides were also developed. Heteroaryl trifluoroborates and aryl chlorides were used as coupling partners in the Suzuki reaction, thereby minimizing detrimental side reactions such as protodeboronation and oxidative homocoupling. A complementary set of reaction conditions using pinacolboronates with potassium bifluoride as an additive were also developed and used to make 5 kg of drug substance for use in early-phase clinical trials.